GPF-DIA and Direct DIA: Which is more suitable for large-scale protein quantification?

In large-scale proteomics studies, Data-Independent Acquisition (DIA) technology has become mainstream due to its high throughput, high reproducibility, and data integrity. However, the development of DIA has also led to various strategies, among whichGPF-DIA (Gas Phase Fractionation DIA) and Direct DIAare the most common. Both have significant differences in library construction methods, experimental processes, and applicable scenarios. This article will systematically compare these two DIA strategies to help researchers make informed decisions based on different research needs.

 

1. What is GPF-DIA?

GPF-DIA is a DIA strategy that enhances library quality throughgas phase fractionation.Researchers fractionate mixed samples in the mass spectrometry m/z dimension (e.g., covering a 100–150 m/z window each time) to achieve higher MS/MS coverage. Subsequently, these high-coverage data are used to constructsample-specific DIA librariesfor subsequent quantitative analysis of large sample batches.

✔ Characteristics of GPF-DIA:

• Deeper protein identification: Suitable for discovering low-abundance and differential proteins.

• Higher library quality: Constructed for target samples, highly representative.

• Better quantitative accuracy: Especially suitable for mechanistic research and biomarker discovery.

• Higher experimental cost: Requires additional runs of multiple gas phase fractionation samples, increasing instrument time and sample consumption.

 

2. What is Direct DIA?

Direct DIA completely skips the library construction step and directly utilizessoftware algorithms (such as DIA-NN, Spectronaut)to identify and quantify proteins from raw DIA data. This 'library-free' approach significantly simplifies the experimental process and has excellent throughput scalability.

✔ Characteristics of Direct DIA:

• Simpler process: No need for fractionation and library acquisition.

• More suitable for high-throughput projects: Such as clinical cohort studies, drug screening, etc.

• Low sample requirement: Suitable for projects where samples are precious or difficult to prepare in batches.

• Slightly lower identification depth: Limited ability to identify extremely low-abundance proteins.

 

3. GPF-DIA vs Direct DIA: Core Metrics Comparison

  

Evaluation Dimension	GPF-DIA	Direct DIA
Protein Identification Depth	Higher, suitable for identifying low-abundance proteins.	Slightly lower, suited for rapid identification of major proteins.
Quantitative Reproducibility	High, suitable for differential protein screening.	Good, meets most quantitative needs.
Experimental Process Efficiency	More complex, requires additional library acquisition.	Simple and efficient, time-saving and sample-conserving.
Data Integrity	Excellent, low loss rate, more stable results.	Slightly inferior to GPF-DIA, but acceptable.
Automation and High-Throughput Capability	Limited by library construction, scalability is limited.	Excellent, suitable for large-scale data processing.
Applicable Sample Types	Studies with sufficient sample volume and clear target exploration.	Studies with limited samples or strong exploratory nature.
Recommended Application Scenarios	Biomarker discovery, mechanistic research, library construction.	Multi-omics integration, clinical cohorts, pharmacodynamic evaluation, and other large-scale projects.

 

4. How to Choose the More Suitable DIA Strategy?

The core of choosing a DIA strategy lies in research goals and resource allocation:

• If you are focused on protein identification depth and quantitative precision, such as disease mechanism analysis, functional protein screening, or library construction, GPF-DIA has more advantages.

• If the study emphasizes sample throughput, data processing efficiency, and automation capability, such as large clinical sample cohorts, pharmacodynamic evaluation, or multi-timepoint intervention experiments, Direct DIA is a more efficient choice.

 

Scientifically selecting DIA strategies according to project needs not only enhances data quality but also significantly optimizes the cost-effectiveness ratio. Biotyper Biotech provides a variety of DIA strategy support to meet a wide range of needs from basic research to clinical translation. Whether your research focuses on exploring biological mechanisms or developing clinical applications, we can provide you with customized proteomics solutions. To learn more about DIA strategy selection advice or obtain typical project cases, feel free to contact us!

 

Biotyper Biotech - A quality service provider for bioproduct characterization and multi-omics mass spectrometry detection

 

Related Services:

DIA Quantitative Proteomics